Cart
sales@molnova.com
ML165
CAS No. 1355454-05-5
ML165( RUC-2 | ML 165 )
Catalog No. M11454 CAS No. 1355454-05-5
A high-affinity, selective platelet integrin αIIbβ3 receptor antagonist with IC50 of 96 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameML165
-
NoteResearch use only, not for human use.
-
Brief DescriptionA high-affinity, selective platelet integrin αIIbβ3 receptor antagonist with IC50 of 96 nM.
-
DescriptionA high-affinity, selective platelet integrin αIIbβ3 receptor antagonist with IC50 of 96 nM; specifically inhibits ligand binding by a novel mechanism, leading to loss of the MIDAS metal ion while producing only minor changes in the conformation of β3.
-
In Vitro——
-
In Vivo——
-
SynonymsRUC-2 | ML 165
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1355454-05-5
-
Formula Weight385.446
-
Molecular FormulaC17H19N7O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C1=CC=C(C=C1)F)NC2=CC(=CC(=N2)NC3=NC=CN=C3)C4=CN(N=C4)C.C(=CC(=O)O)C(=O)O
-
Chemical Name2-amino-N-(3-(5-oxo-7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)phenyl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhu J, et al. Sci Transl Med. 2012 Mar 14;4(125):125ra32.
2. Jiang JK, et al. Bioorg Med Chem Lett. 2014 Feb 15;24(4):1148-53.
molnova catalog
related products
-
RBC8
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
-
Echistatin, α1 isofo...
Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3) receptors (IC50 = 30 nM) in vitro.
-
Natalizumab
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
